Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b

László Kalabay, Elemér Nemesánszky, Antal Csepregi, Mária Pusztay, Károly Dávid, Gábor Horváth, Ervin Ibrányi, László Telegdy, Alajos Pár, Adrienn Bíró, Béla Fekete, Judith Gervain, Margit Horányi, Pál Ribiczey, Mihály Csöndes, Mónika Kleiber, Szilvia Walentin, Zoltán Prohászka, George Füst

Research output: Contribution to journalArticle

21 Citations (Scopus)


Previously we observed elevation of the serum concentration of two acute-phase protein (AFP) complement components (C9 and C1-inhibitor) in patients with chronic hepatitis C who responded (R) to IFN-α therapy, but not in non-responders (NR). In the present study we investigated the effect of high-dose IFN-α therapy on serum concentrations of two positive [orosomucoid (OROSO) and C-reactive protein (CRP)] and two negative [transferrin (TF) and fetuin/α2HS-glycoprotein (AHSG)] AFP in an outpatient setting. We investigated blood samples of 40 patients with chronic hepatitis C at the onset and at the end of a 3-month treatment with high-dose IFN-α2b (5 MIU/day for 6 weeks, followed by 5 MIU t.i.w.) and of 52 healthy individuals. Serum concentrations of OROSO, TF and AHSG were measured by radial immunodiffusion; CRP levels were determined by immunotubridimetry. Compared to controls, patients with chronic hepatitis C had significantly lower OROSO and CRP, and higher AHSG levels. By the end of treatment, OROSO concentration increased in R (P = 0.0054), but not in NR patients. In contrast, TF levels decreased in R (P = 0.0040), but did not change in NR patients. Similarly, in R patients, AHSG levels tended to decrease (P = 0.0942) following IFN-α treatment. We conclude that the acute-phase reaction is suppressed in patients with chronic hepatitis C that may be potentially related to the responsiveness to IFN-α therapy.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalInternational Immunology
Issue number1
Publication statusPublished - Jan 1 2004



  • Chronic hepatitis C
  • Fetuin/α2HS-glycoprotein
  • IFN-α therapy
  • Orosomucoid
  • Transferrin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Kalabay, L., Nemesánszky, E., Csepregi, A., Pusztay, M., Dávid, K., Horváth, G., Ibrányi, E., Telegdy, L., Pár, A., Bíró, A., Fekete, B., Gervain, J., Horányi, M., Ribiczey, P., Csöndes, M., Kleiber, M., Walentin, S., Prohászka, Z., & Füst, G. (2004). Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b. International Immunology, 16(1), 51-54.